Reuters logo
BRIEF-Chi-Med reports preliminary phase II data on fruquintinib combination
2017年10月16日 / 早上6点21分 / 1 个月前

BRIEF-Chi-Med reports preliminary phase II data on fruquintinib combination

Oct 16 (Reuters) - Hutchison China Meditech Ltd

* CHI-MED REPORTS PRELIMINARY PHASE II DATA ON FRUQUINTINIB COMBINATION IN FIRST-LINE LUNG CANCER

* HUTCHISON CHINA MEDITECH LTD SAYS ‍PRELIMINARY RESULTS IN 17 EFFICACY EVALUABLE PATIENTS SHOWED AN ORR OF 76 PERCENT AND A DCR OF 100 PERCENT​

* HUTCHISON CHINA MEDITECH LTD SAYS ‍PRELIMINARY DATA FROM PHASE II TRIAL DEMONSTRATED PROMISING EFFICACY AND AN ACCEPTABLE SAFETY PROFILE​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below